Articles tagged "HLA antibodies"

2021 American Transplant Congress
Impact of Rituximab Induction Therapy on Donor-specific Anti-HLA Antibodies in Abo-compatible Kidney Transplant Recipients
T. Yagisawa¹, T. Kanzawa¹, K. Unagami², M. Furusawa¹, M. Inui¹, H. Ishida², K. Tanabe¹
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Development of de novo donor-specific anti-HLA antibodies (dnDSA) after kidney transplantation remains strongly associated with antibody-mediated rejection (AMR), which leads to poor graft outcome.…
2021 American Transplant Congress
Transplant Glomerulopathy in the Absence of Donor-specific HLA Antibodies: Risk Factors, Histopathological Features and Graft Outcome
A. Senev, E. Van Loon, M. Emonds, M. Naesens
Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
*Purpose: Transplant glomerulopathy (TG) is established as a hallmark of chronic antibody-mediated rejection in kidney transplant patients with donor-specific HLA antibodies (HLA-DSA). The clinical importance…
2021 American Transplant Congress
The Use of Donor Derived Cell Free DNA in Children to Monitor Therapy of Kidney Rejection
A. Al-Uzri, M. Wright, K. Clark, R. Jenkins
Oregon Health & Science Univ, Portland, OR
*Purpose: Elevated donor-derived cell-free DNA (dd-cfDNA) in the presence of HLA donor-specific antibodies (DSA) are shown to correlate with acute antibody-mediated rejection (AMR) in adult…
2021 American Transplant Congress
High Donor-Derived Cell-Free DNA Levels Predict Development of De Novo HLA Donor-Specific Antibodies After Kidney Transplantation – Data from the ADMIRAL Study
G. Gupta¹, T. Alhamad², V. Bowers³, I. Moinuddin¹, S. Ghosh⁴, J. Zeng⁴, E. Stites⁵, A. Pai⁶, J. S. Bromberg⁷, S. Anand⁸
¹Virginia Commonwealth University, Richmond, VA, ²Washington University in St. Louis, St. Louis, MO, ³Tampa General Hospital, Tampa, FL, ⁴CareDx, Brisbane, CA, ⁵University of Colorado, Aurora, CO, ⁶University of Texas McGovern Medical School, Houston, TX, ⁷University of Maryland School of Medicine, Baltimore, MD, ⁸Intermountain Medical Center, Murray, UT
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) as a marker of injury can serve to quantify subclinical inflammation and molecular injury. As the release of graft genomic…
2021 American Transplant Congress
Bortezomib for Antibody-Mediated Rejection of Renal Transplant in Youth
L. Galea, J. Hewlett, J. Savant, S. Lopez, S. Amaral, B. Viteri
The Children’s Hospital of Philadelphia, Philadelphia, PA
*Purpose: The purpose of the study was to examine preliminary efficacy and tolerability of bortezomib, a protease inhibitor, in treatment-refractory antibody mediated rejection (AMR) in…
2021 American Transplant Congress
Prospective Intensive Monitoring for Anamnestic DSA Responses Allows Near Elimination of Early Clinical AMR
M. McGowan¹, A. Bickenbach¹, A. R. Shields², R. R. Alloway¹, P. Brailey¹, E. Portwood¹, C. Alquist¹, A. Christianson¹, B. Abu Jawdeh¹, M. Cuffy¹, J. Kremer², S. Bumb¹, A. Govil¹, M. Anand¹, T. Kaur¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: Anamnestic donor specific antibody (aDSA) responses can result in severe, graft threatening antibody-mediated rejection (AMR). We hypothesized that intensive DSA monitoring (IDM) for aDSA…
2021 American Transplant Congress
Membrane versus Centrifuge‑Based Therapeutic Plasma Exchange to Treat Antibody-Mediated Rejection in Kidney Transplantation
P. Maggiani¹, J. C. Ramirez Valdestino¹, J. H. Cano Cervantes¹, O. D. Díaz Avedaño¹, G. García Castillo¹, M. C. Oseguera Vizcaíno², M. A. Covarrubias², M. Matías Carmona¹, D. F. Ovando Morga¹, G. Ramirez Ramirez¹, V. D. Lebrija Córdoba¹, S. Hernandez Estrada¹
¹Transplantation, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico, ²Transplantation, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico
*Purpose: Therapeutic plasma exchange (TPE) is either performed using a highly permeable filter with standard multifunctional renal replacement equipment (mTPE) or a centrifugation device (cTPE).…
2021 American Transplant Congress
Is There a Role for Donor-Specific Antibody Testing in Simultaneous Liver-Kidney Transplantation? A Single Center Analysis of Outcomes
A. Das, A. Barbetta, D. Remulla, C. Goldbeck, T. Maw, J. Kim
University of Southern California, Los Angeles, CA
*Purpose: Simultaneous liver-kidney transplantation (SLKT) has grown exponentially since its conception in the 1960’s. The role for donor specific antibody (DSA) testing in SLKT is…
2021 American Transplant Congress
De Novo Membranous Nephropathy Associated with Antibody-mediated Rejection in Renal Transplant Recipients
M. V. Sousa¹, L. G. Fernandes², L. L. de Freitas³, R. L. Zollner², M. Mazzali¹
¹Internal Medicine - Division of Nephrology, University of Campinas, Campinas, Brazil, ²Internal Medicine, University of Campinas, Campinas, Brazil, ³Pathology, University of Campinas, Campinas, Brazil
*Purpose: Membranous nephropathy (MN) is a rare autoimmune disease, with the potential to develop a persistent nephrotic syndrome and end-stage chronic renal disease in some…
2021 American Transplant Congress
Relationship Between %dd-cfDNA, MMDx Molecular Diagnoses, and Donor-specific Antibody in the Trifecta Study
P. F. Halloran¹, L. G. Hildago², J. Reeve¹, Z. Demko³, A. Prewett³, P. Billings³, J. Truong⁴, P. Vander Horn⁴, &. Trifecta Study Group⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: The Trifecta Study is a prospective multicenter investigator-initiated trial to evaluate the relationship between %dd-cfDNA and molecular biopsy findings at the time an indication…

« Previous Page
1
…
3
4
5
6
7
…
47
Next Page »